Aims Patients with atrial fibrillation (AF) are at increased risk of stroke. Betrixaban is a novel
oral factor Xa inhibitor administered once daily, mostly excreted unchanged in the bile and …

The recently introduced oral anticoagulants, dabigatran, rivaroxaban and apixaban, were
shown, in randomized controlled trials, to be at least as effective and safe as monitored …

Background Vitamin K antagonists are highly effective in preventing stroke in patients with
atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa …

Objectives: This study sought to characterize major bleeding on the basis of the components
of the major bleeding definition, to explore major bleeding by location, to define 30-day …

Background Patients with atrial fibrillation who are vitamin K antagonist (VKA)-naive may
have a higher risk of thrombosis and/or bleeding than VKA-experienced patients. Methods …

Background—Dabigatran, an oral thrombin inhibitor, and rivaroxaban and apixaban, oral
factor Xa inhibitors, have been found to be safe and effective in reducing stroke risk in …

Abstract Aim In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced the risk of …

Background The use of warfarin reduces the rate of ischemic stroke in patients with atrial
fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor …

BACKGROUND: The use of warfarin reduces the rate of ischemic stroke in patients with
atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral …

Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …